CO68 Pooled Subgroup Analysis of Patient-Reported Outcomes at Week 52 Among Patients Achieving the Primary Endpoint of F-VASI75 at Week 24 in Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.147
https://www.valueinhealthjournal.com/article/S1098-3015(22)02351-8/fulltext
Title :
CO68 Pooled Subgroup Analysis of Patient-Reported Outcomes at Week 52 Among Patients Achieving the Primary Endpoint of F-VASI75 at Week 24 in Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02351-8&doi=10.1016/j.jval.2022.09.147
First page :
Section Title :
Open access? :
No
Section Order :
11027